Area of research
Public Health, Environmental and Occupational Health · Pediatrics, Perinatology and Child Health
Research interest
Research focused on Cohort and Cytarabine, with related work in Lymphoblastic Leukemia, Cancer research, Etoposide. Notable publications include 'Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)', 'FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631', and 'Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children’s Oncology Group Study AALL1131'.
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study
Outstanding outcomes in infants with <i>KMT2A</i>-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children’s Oncology Group Study AALL1131
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131
Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced‐dose chemotherapy on Children's Oncology Group trial A2971